SC 13G/A
1
upc.txt
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(AMENDMENT NO. 1)*
Universe Pharmaceuticals Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
G9442G104
(CUSIP Number)
December 31, 2022
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant
to which this Schedule is filed:
[ ] Rule 13d-1(b)
[X ] Rule 13d-1(c)
[ ] Rule 13d-1(d)
* The remainder of this cover page shall be filled out
for a reporting person's initial filing on this form
with respect to the subject class of securities, and
for any subsequent amendment containing information
which would alter disclosures provided in a prior
cover page.
The information required on the remainder of this cover
page shall not be deemed to be "filed" for the purpose of
Section 18 of the Securities Exchange Act of 1934 ("Act")
or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of
the Act (however, see the Notes).
CUSIP No. G9442G104
13G
Page 2 of 7 Pages
1.
NAMES OF REPORTING PERSONS OR
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Pura Vida Investments, LLC
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a) [ ]
(b) [ x ]
3.
SEC USE ONLY
4.
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
5.
SOLE VOTING POWER
0
6.
SHARED VOTING POWER
0
7.
SOLE DISPOSITIVE POWER
0
8.
SHARED DISPOSITIVE POWER
0
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0
10.
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) [ ]
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0%
12.
TYPE OF REPORTING PERSON (see instructions)
IA
CUSIP No. G9442G104
13G
Page 3 of 7 Pages
1.
NAMES OF REPORTING PERSONS OR
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Efrem Kamen
2.
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a) [ ]
(b) [ x ]
3.
SEC USE ONLY
4.
CITIZENSHIP OR PLACE OF ORGANIZATION
United States of America
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
5.
SOLE VOTING POWER
0
6.
SHARED VOTING POWER
0
7.
SOLE DISPOSITIVE POWER
0
8.
SHARED DISPOSITIVE POWER
0
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
0
10.
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions) [ ]
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0%
12.
TYPE OF REPORTING PERSON (see instructions)
IN, HC
CUSIP No. G9442G104
13G
Page 4 of 7 Pages
Item 1.
(a)
Name of Issuer
Universe Pharmaceuticals Inc.
(b)
Address of Issuers Principal Executive Offices
265 Jingjiu Avenue
Jinggangshan Economic and Technological Development Zone
Jian, Jiangxi, China 343100
Item 2.
(a)
Name of Person Filing
Pura Vida Investments, LLC
Efrem Kamen
(collectively, the "Filers").
(b)
The address of the principal place of the Filers is located at:
Pura Vida Investments, LLC, 512 West 22nd Street, 7th Floor, New York, NY 10022
(c)
For citizenship of Filers, see Item 4 of the cover sheet for each Filer.
(d)
Title of Class of Securities
Common Stock
(e)
CUSIP Number
G9442G104
Item 3. If this statement is filed pursuant to Rules 13d-1(b)
or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
[ ]
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
(b)
[ ]
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c)
[ ]
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
(d)
[ ]
Investment company registered under section 8 of the
Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e)
[X]
An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
CUSIP No. G9442G104
13G
Page 5 of 7 Pages
(g)
[ ]
A parent holding company or control person in accordance with Rule
13d-1(b)(1)(ii)(G);
(h)
[ ]
A savings associations as defined in Section 3(b) of the
Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
[ ]
A church plan that is excluded from the definition of an
investment company under section 3(c)(14) of the Investment
Company Act of 1940 (15 U.S.C. 80a-3);
(j)
[ ]
Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
Item 4. Ownership.
(a) Amount beneficially owned:
Pura Vida Investments, LLC 0 shares
Efrem Kamen 0 shares
(b) Percent of class:
Pura Vida Investments, LLC 0%
Efrem Kamen 0%
(c) Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote
0
(ii) Shared power to vote or to direct the vote
Pura Vida Investments, LLC 0 shares
Efrem Kamen 0 shares
(iii) Sole power to dispose or to direct the disposition of
0
(iv) Shared power to dispose or to direct the disposition of
Pura Vida Investments, LLC 0 shares
Efrem Kamen 0 shares
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that
as of the date hereof the Reporting Persons have ceased
to be the beneficial owners of more than five percent
of the class of securities, check the following: ?
CUSIP No. G9442G104
13G
Page 6 of 7 Pages
Item 6. Ownership of More than Five Percent on Behalf
of Another Person.
N/A
Item 7. Identification and Classification of the
Subsidiary Which Acquired the Security Being
Reported on By the Parent Holding Company.
N/A
Item 8. Identification and Classification of Members of the Group.
N/A
Item 9. Notice of Dissolution of Group.
N/A
Item 10. Certification.
By signing below, I certify that, to the best of
my knowledge and belief, the securities referred to above
were not acquired and are not held for the purpose of or
with the effect of changing or influencing the control of
the issuer of the securities and were not acquired and
are not held in connection with or as a participant in any
transaction having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge
and belief, I certify that the information set forth in
this statement is true, complete, and correct.
Dated: February 14, 2023
Pura Vida Investments, LLC
________________________________________
By: /s/ Efrem Kamen, Managing Member
CUSIP No. G9442G104
13G
Page 7 of 7 Pages
EXHIBIT A
AGREEMENT REGARDING JOINT FILING
OF STATEMENT ON SCHEDULE 13D OR 13G
The undersigned hereby consent and agree to file
a joint statement on Schedule 13G under the
Securities Exchange Act of 1934, as amended, with
respect to the Pura Vida Investments, LLC. beneficially
owned by them, together with any or all amendments
thereto, when and if appropriate. The parties hereto
further consent this Statement pursuant to
Rule 13d-1(k)(1)(iii) as an exhibit to Schedule 13G,
thereby incorporating the same into such Schedule 13G.
Dated: February 14, 2023
Pura Vida Investments, LLC
By: /s/ Efrem Kamen, Managing Member
Jiangxi, China, March 20, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ:UPC) ("Universe Pharmaceuticals" or the "Company"), a pharmaceutical producer and distributor in China, today announced that the Company plans to effect a share consolidation of 40 ordinary shares with par value of US$0.28125 per share each in the Company's issued and unissued share capital into one (1) ordinary share with par value of US$11.25 (the "Share Consolidation"). As a result of the Share Consolidation, each 40 pre-consolidation ordinary shares outstanding will automatically combine and convert to one issued and outstanding ordinary share without any action on the part of the shareholders. Th
Ji'an, Jiangxi, China, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the "Company") (NASDAQ:UPC), a pharmaceutical producer and distributor in China, today announced that on February 19, 2025, the Company received a staff determination notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it is delinquent in filing its Annual Report on Form 20-F for the fiscal year ended September 30, 2024 (the "Form 20-F") and that this matter serves as an additional basis for delisting the Company's securities from Nasdaq. The failure to timely file the Form 20-F is a violation of Nasdaq Listing Rule 5250(c)(1). The Com
Ji'an, Jiangxi, China, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the "Company") (NASDAQ:UPC), a pharmaceutical producer and distributor in China, today announced that the Company received a letter from the Nasdaq Stock Market LLC ("Nasdaq") on January 29, 2025, notifying the Company that the Nasdaq staff has determined to delist the Company's ordinary shares from The Nasdaq Capital Market (the "Delisting Determination"), because the bid price of the Company's listed securities has closed at less than $1 per share over the previous 30 consecutive business days, and therefore no longer complies with the Nasdaq Listing Rule 5550(a)(2) (the "Rule"). Normally, a company w
Ji'an, Jiangxi, China, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the "Company") (NASDAQ:UPC), a pharmaceutical producer and distributor in China, today announced that the Company appointed Mr. Baochang Liu as its Chief Operating Officer, effective December 1, 2021. Mr. Baochang Liu has over 17 years of experience in pharmaceutical marketing. Mr. Baochang Liu has been working as the vice president of marketing and general manager of OTC department at China Shineway Pharmaceutical Group Ltd. since December 2019. Mr. Baochang Liu served as the general manager of OTC department at Chengdu Kanghong Pharmaceutical Group Co., Ltd. from November 2015 to December 2019. Prior
